Harvest Fund Management Co. Ltd Has $582,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Harvest Fund Management Co. Ltd lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 124.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 5,626 shares of the company’s stock after buying an additional 3,120 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in Novo Nordisk A/S were worth $582,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Clarius Group LLC grew its holdings in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock valued at $1,914,000 after purchasing an additional 93 shares during the last quarter. Tradewinds Capital Management LLC boosted its position in Novo Nordisk A/S by 2.0% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock worth $513,000 after buying an additional 95 shares during the period. Relyea Zuckerberg Hanson LLC boosted its position in Novo Nordisk A/S by 3.2% during the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock worth $327,000 after buying an additional 99 shares during the period. Fort Washington Investment Advisors Inc. OH boosted its position in Novo Nordisk A/S by 3.5% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock worth $306,000 after buying an additional 100 shares during the period. Finally, Highlander Capital Management LLC boosted its position in Novo Nordisk A/S by 0.4% during the 4th quarter. Highlander Capital Management LLC now owns 25,100 shares of the company’s stock worth $2,597,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NVO. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Down 1.9 %

Shares of NYSE NVO traded down $2.48 during trading on Wednesday, hitting $126.16. The stock had a trading volume of 3,092,421 shares, compared to its average volume of 4,833,965. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The company has a market capitalization of $566.15 billion, a PE ratio of 46.42, a PEG ratio of 2.09 and a beta of 0.41. The firm has a fifty day moving average of $126.66 and a two-hundred day moving average of $111.54.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This represents a yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is presently 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.